Updated:
SK Biopharmaceuticals
SK Biopharmaceuticals was founded in 2011 as a standalone life-science subsidiary of SK Group, the South Korean conglomerate controlled by Chairman Chey...
SK Biopharmaceuticals
SK Biopharmaceuticals was founded in 2011 as a standalone life-science subsidiary of SK Group, the South Korean conglomerate controlled by Chairman Chey Tae-won. The firm inherited SK's drug-discovery programs and was structured to carry assets from lab to market without relying on a global pharma partner for commercialization. Chairman Chey's daughter, Chey Yoon-chung, serves as Vice President and Head of Strategy, while day-to-day operations run under CEO and President Donghoon Lee. The company concentrates R&D on central nervous system disorders, with a pipeline that has broadened to include targeted protein degradation and neuro-immune assets. Its anchor product, cenobamate, is an antiepileptic drug sold in the U.S. through the wholly owned subsidiary SK Life Science, headquartered in Paramus, New Jersey. The drug's U.S. commercial ramp — reported by the firm in May 2026 as accelerating growth and record performance — funds further pipeline investment. Beyond internal R&D, the firm pursues strategic alliances and open-innovation partnerships with domestic biotech startups, leveraging its experience with global regulatory filings. SK Biopharmaceuticals maintains a U.S. commercial infrastructure, a discovery lab in King of Prussia, Pennsylvania, and an office in Shanghai. Chairman Chey Tae-won also leads the Korea Chamber of Commerce and Industry, anchoring the company within a broad domestic industrial network. May 2026: SK Biopharmaceuticals publicly outlined a next-generation pipeline strategy centered on targeted protein degradation, a modality gaining traction across the industry. The firm's structural distinction is vertical integration: it owns U.S.-based clinical development, regulatory affairs, and a branded sales force for neurology — an operating posture rarely seen in Asian pharma companies that more commonly out-license lead assets to Western partners before commercialization.
General information
Firm type
Corporate Investor
Year founded
2011
AUM
Undisclosed
Location
Region
Asia
Country
South Korea
City
Seongnam-si
Corporate office
221, Pangyoyeok-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13494, South Korea
Additional offices
Paramus, NJ, United States · King of Prussia, PA, United States · Shanghai, China
Principals
Chey Tae-won
Chairman of SK Group
Chey Yoon-chung
Vice President and Head of Strategy
Donghoon Lee
CEO and President
Sector focus
Frequently asked questions
Who controls SK Biopharmaceuticals?
SK Biopharmaceuticals is a corporate subsidiary of SK Group, the South Korean conglomerate. Chairman Chey Tae-won is the ultimate controlling person, with the parent holding company SK Inc. owning approximately 50 to 64 percent of the firm. His daughter Chey Yoon-chung holds an executive role as Vice President and Head of Strategy.
What therapeutic areas does SK Biopharmaceuticals focus on?
The firm concentrates its discovery and development resources on central nervous system disorders. Its commercial-stage product cenobamate treats epilepsy, and its internal pipeline has expanded into neuro-immune indications and targeted protein degradation modalities, as outlined in its May 2026 R&D strategy presentation.
Does SK Biopharmaceuticals operate only in South Korea?
No. While the company is headquartered in Seongnam-si, South Korea, it maintains a substantial U.S. operational footprint. The wholly owned subsidiary SK Life Science handles U.S. commercial sales from Paramus, New Jersey, and SK Life Science Labs conducts discovery research from King of Prussia, Pennsylvania. An additional office exists in Shanghai.
How does SK Biopharmaceuticals commercialize its drugs?
Unlike many Korean drug developers that license lead assets to Western pharma companies, SK Biopharmaceuticals built its own U.S. commercial infrastructure to launch cenobamate directly. The firm operates a branded sales force through its subsidiary SK Life Science, handling U.S. marketing, sales, and distribution internally.
Is SK Biopharmaceuticals involved in open innovation or partnering?
Yes. The firm has entered open-innovation partnerships with domestic biotech startups, as demonstrated by a collaboration with Seoul Biohub to share drug-development know-how. It also maintains a strategic-alliance function to pursue external opportunities that complement its internal CNS pipeline.
Does the firm have any philanthropic or ESG commitments?
The SK Group network includes the SK Happiness Foundation. On the ESG front, SK Biopharmaceuticals is a member of the Pharmaceutical Supply Chain Initiative, the first Korean biopharmaceutical company to join, and publicly reports on areas including SHE management, access to healthcare, and anti-corruption governance.
How is the firm structurally positioned within SK Group?
SK Biopharmaceuticals operates as an independent, publicly listed subsidiary of SK Inc., the holding company of SK Group. This structure allows dedicated capital allocation to CNS drug development while maintaining strategic alignment with the broader conglomerate, which spans energy, semiconductors, and telecommunications.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: